Status:

COMPLETED

Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab

Lead Sponsor:

Daewoong Pharmaceutical Co. LTD.

Conditions:

Hypertension

Dyslipidemia

Eligibility:

All Genders

19+ years

Brief Summary

Throughout this study, the efficacy and safety information of Olomax tablets will be collected from 24 weeks to 48 weeks(+8 weeks) The Data collection point is baseline, at more than 24 weeks, at more...

Detailed Description

The study will start after investigator determines the administration of Olomax tablets based on the investigator's judgement and obtaining informed consent from the subject during subject's daily vis...

Eligibility Criteria

Inclusion

  • Adults over the age of 19
  • Patients eligible for Olomax Tab. prescription in accordance with the approved product manual in Korea
  • Patients who are determined to prescribe Olomax Tab. at the discretion of the investigators.
  • Antihypertensive agent: Do not include more than 3 agents.
  • Anti-abnormal lipidemia: Do not include more than 2 agents.
  • Subjects who are already administered beta blocker (BB) or diuretics due to other diseases such as angina, not for the purpose of treating hypertension may be included.
  • Consent on the use of information by the patient

Exclusion

  • Patients who have already administered olomax tablets.
  • Subject who fall under ' Do not administer to the following patients' in the precautions for use
  • A patient who does not meet the inclusion/exclusion criteria participates
  • The patient withdraws consent for the study
  • The administration of the study drug is discontinued
  • It is impossible to follow up during the observation period
  • The investigator determines that it is no longer feasible to continue the study

Key Trial Info

Start Date :

December 1 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 16 2022

Estimated Enrollment :

5450 Patients enrolled

Trial Details

Trial ID

NCT05184179

Start Date

December 1 2019

End Date

August 16 2022

Last Update

July 1 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hallym University Dongtan Sacred Heart Hospital

Hwaseong-si, Gyeonggi-do, South Korea, 18450